ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,401.60
0.50%
S&P ASX All Technology
3,912.80
0.54%
Brent Oil
72.205
-0.34%
US Dollar vs AUD
1.54398
-0.04%
Bitcoin
92,714.75
0.81%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) News

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RARE
DateTimeSourceHeadlineSymbolCompany
27/11/202408:30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in DecemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
21/11/202408:30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
12/11/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
10/11/202402:30GlobeNewswire Inc.Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/11/202408:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/11/202408:01GlobeNewswire Inc.Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/10/202407:05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
19/10/202407:30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
12/10/202407:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/10/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
07/10/202423:00GlobeNewswire Inc.Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis ImperfectaNASDAQ:RAREUltragenyx Pharmaceutical Inc
04/10/202406:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
04/10/202406:30GlobeNewswire Inc.Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
26/09/202422:00GlobeNewswire Inc.Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
19/09/202407:00GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
19/09/202403:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
06/09/202401:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
30/08/202406:30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in SeptemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
23/08/202421:00Business WireTactical Resources, a Growing North American Rare Earth Elements Company, to List on NASDAQNASDAQ:RAREUltragenyx Pharmaceutical Inc
22/08/202406:30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
02/08/202406:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
02/08/202406:05GlobeNewswire Inc.Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
26/07/202406:05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
24/07/202422:00GlobeNewswire Inc.Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumNASDAQ:RAREUltragenyx Pharmaceutical Inc
20/07/202406:05GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
18/07/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
18/07/202406:05GlobeNewswire Inc.Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome ProgramNASDAQ:RAREUltragenyx Pharmaceutical Inc
13/07/202406:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAREUltragenyx Pharmaceutical Inc
21/06/202406:30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
21/06/202404:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:RARE

Your Recent History

BIT
PETZ
Rize Pet Care UCITS ETF ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36